(Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） （Stock Code 股份代號：0690） NOTIFICATION LETTER 通知信函 Dear Registered Shareholders, Uni-Bio Science Group Limited (the "Company") – Notification of Publication of Annual Report 2024; Circular dated 22 April 2025 relating to Grant of General Mandates to Issue and Repurchase Shares, Re-Election of Directors, Declaration of Final Dividend; Notice of Annual General Meeting; and Form of Proxy ("Current Corporate Communications") The English a ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 通 告 之 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 本 通 告 全 部 或 任 何 部 分 內 容 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 UNI-BIO SCIENCE GROUP LIMITED 聯康生物科技集團有限公司* （股份代號：0690） 股 東 週 年 大 會 通 告 茲通告聯康生物科技集團有限公司（「本公司」）謹訂於二零二五年五月二十六日（星 期 一）上 午 十 時 三 十 分 假 座 香 港 新 界 沙 田 香 港 科 學 園 科 技 大 道 東20號5樓502 室 舉 行 股 東 週 年 大 會，藉 以 考 慮 及 酌 情 處 理 下 列 事 項： * 僅 供 識 別 – 1 – 1. 省 覽 及 採 納 本 公 司 及 其 附 屬 公 司 截 至 二 零 二 四 年 十 二 月 三 十 一 日 止 年 度 之 經 審 核 綜 合 財 務 報 表 及 本 ...

此 乃 要 件 請 即 處 理 閣 下 如 對 本 通 函 任 何 方 面 或 應 採 取 之 行 動 有 任 何 疑 問，應 諮 詢 閣 下 之 持 牌 證 券 商、 銀 行 經 理、律 師、專 業 會 計 師 或 其 他 專 業 顧 問。 閣 下 如 已 將 名 下 之 聯 康 生 物 科 技 集 團 有 限 公 司（「本 公 司」）股 份 全 部 售 出 或 轉 讓，應 立 即 將 本 通 函 及 隨 附 之 代 表 委 任 表 格 送 交 買 主、承 讓 人 或 經 手 買 賣 或 轉 讓 之 銀 行、持 牌 證 券 商 或 其 他 代 理 商，以 便 轉 交 買 主 或 承 讓 人。 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 通 函 之 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 通 函 全 部 或 任 何 部 份 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 UNI-BIO SCIENC ...

Financial Performance - Revenue for the year ended December 31, 2024, reached HKD 552.98 million, representing a year-on-year growth of 14.1%[15] - Gross profit increased to HKD 461.07 million, with a gross margin of 83.4%[15][16] - Adjusted EBITDA for the year was HKD 122.46 million, up from HKD 99.45 million in the previous year[15] - In 2024, the company achieved significant growth in revenue and profit, with sales of the newly launched drug Bogu Tai® exceeding HKD 63.0 million within the first ten months[22] - The company recorded revenue of approximately HKD 553.0 million in 2024, representing a year-on-year growth of 14.1%[58] - Gross profit increased to approximately HKD 461.1 million, up 17.4% from HKD 392.8 million in 2023, with a gross margin of 83.4%[58] - The company achieved a record profit of approximately HKD 82.8 million in 2024, marking a significant year-on-year growth of 16.8%[58] - The sales of the company's flagship product, Jin Yin Peptide®, generated approximately HKD 197.9 million, a year-on-year increase of 6.7%[60] - Sales of biopharmaceuticals reached approximately HKD 303.4 million, a significant increase of 33.7% year-on-year, accounting for 54.9% of total sales[67] Research and Development - Research and development expenses amounted to HKD 52.28 million, accounting for 9.5% of total revenue[15][17] - The company has established two proprietary R&D platforms to support research projects, focusing on cost-effective large-scale production and drug delivery applications[25] - The company continues to focus on R&D in endocrine diseases, ophthalmology, and dermatology, with multiple products at various development stages[42] - The patented drug Uni-PTH effectively treats osteoporosis and bone pain, increasing bone density and reducing fracture risk within a six-month treatment period[44] - The company is exploring innovative applications, including third-generation microneedle formulations and new target antibody drugs for weight loss treatment[23] - The company’s R&D expenses grew by 47% to approximately HKD 52.3 million, aligning with its multi-pipeline research progress[58] - The group is advancing its R&D pipeline with significant progress in biopharmaceuticals, including the development of a PTH microneedle patch and a new weight-loss antibody drug[76] Product Development and Launches - The launch of 博固泰® marks a significant breakthrough in osteoporosis and orthopedic disease management, expanding the product portfolio[11] - The company is entering the medical aesthetics sector with the introduction of 肌顏態®[21] - The company plans to expand the product line of Ji Yan Tai® in 2025, introducing high-end skin repair anti-aging series and daily care masks and serums to meet diverse market demands[22] - The company has launched six products in the market as of December 31, 2024, including Jinyin Peptide®, Jinyin Shu®, and Bogu Tai®[35] - The company introduced a new medical beauty product, JiYanTai®, in December 2024, which is based on proprietary technology and aims to enhance skin quality and promote tissue repair[40] - The company is advancing its clinical research on BoguTai® focusing on fracture prevention and pain management, further enhancing its market presence[39] - The company has submitted supplementary data for Diquafosol Sodium eye drops to the CDE, expecting market approval in the first half of 2025, which will enhance its ophthalmic product portfolio[23] Market Expansion and Strategy - The company is actively enhancing its sales and marketing strategies, reducing reliance on existing markets and channels, and expanding into overseas markets, including initiating FDA application procedures for its self-developed biopharmaceutical PTH product[25] - The Chinese medical aesthetics market is expected to grow by approximately 10% in 2024, with a projected growth rate of 10-15% over the next four years, indicating a positive development outlook[34] - The company aims to maintain its leading position in orthopedic applications while expanding into endocrinology, pain management, rheumatology, immunology, and geriatrics[79] - The group aims to expand its sales channels beyond traditional hospitals to include pharmacies, online platforms, and aesthetic medical institutions[75] Corporate Governance and Management - The board welcomed new members, including Dr. Wen Yalei as Executive Director and COO, and Ms. Zhang Qing as Non-Executive Director, enhancing the company's strategic vision and commitment to innovation[27] - The company’s management team includes experienced professionals with backgrounds in finance, corporate management, and biotechnology[111][112] - The board consists of seven members, including three executive directors and three independent non-executive directors, ensuring compliance with listing rules[124] - The company adheres to corporate governance principles to enhance shareholder value and maintain investor confidence[123] - The company has implemented appropriate liability insurance for directors to cover responsibilities arising from business operations[129] Financial Health and Ratios - The cash ratio improved to 2.00, up from 1.13 in the previous year, indicating better liquidity[13] - The current ratio increased to 3.00, compared to 2.07 in the previous year, reflecting enhanced short-term financial health[13] - The debt-to-equity ratio slightly decreased to 58.9% from 59.4%, indicating a stable capital structure[13] Shareholder Returns - The company announced its first dividend, committing to distribute 20% of net profit as dividends, reflecting a strong commitment to shareholder value[21] - The company has proposed a final dividend of HKD 0.277 per share, marking its first dividend distribution, reflecting confidence in its performance[37] - The final dividend is contingent upon certain conditions being met, with an expected payment date around June 13, 2025[90] Sustainability and Ethics - The company is committed to high standards of business ethics and integrity, ensuring all employees adhere to a long-established code of conduct[176] - The company maintains a commitment to environmental sustainability by encouraging electronic communication to reduce printed materials[170] Employee and Director Information - The group employs a total of 487 staff, including 34 in R&D, 223 in production, and 156 in commercial offices in China, with competitive compensation to attract and retain talent[88] - The company has achieved gender diversity among employees with a male-to-female ratio of 100:100, compared to 97:100 last year[163] - The board currently consists of 8 male directors and 1 female director, with a target to increase the female director ratio to over 10% in the coming years[162]

提名委員會職權範圍 提名委員會 UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） （「本公司」） 本 公 司 的 董 事 會（「 董 事 會 」已 成 立 一 個 董 事 會 委 員 會 稱 為 提 名 委 員 會（「 委 員 會」），其組成及職責如下： (a) 委 員 會 成 員 由 董 事 會 委 任 。 該 委 員 會 由 不 少 於 三 名 成 員 組 成 ， 其 中 大 部 份 應 該 是 本 公 司 的 獨 立 非 執 行 董 事（「 獨 立 非 執 行 董 事」）。 委 員 會 的 成 員 應 至 少 有 一 位 為 熟 悉 本 公 司 日 常 運 作 的 執 行 董 事 或 非 執 行 董 事 委 員 會 的 組 成 應 遵 守 香 港 聯 合 交 易 所 有 限 公 司 不 時 修 定 之 證 券 上 市 規 則「 上 市 規 則」的規定。 (b) 委員會主席必須是董事會主席或獨立非執行董事。 (c) 提名委員會須由不同性別組成。 (a) 每次會議的法定人數應為兩位成員。 ( ...

UNI-BIO SCIENCE GROUP LIMITED 執行董事 梁國龍先生 （ 主席 ） 陳大偉先生 （ 副主席 ） 趙志剛先生 （ 行政總裁 ） 聞亞磊博士 （ 首席營運官 ） 非執行董事 邱國榮先生 張清女士 獨立非執行董事 周啓明先生 任啓民先生 馬青山先生 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 董事名單與其角色和職能 自二零二五年三月二十七日起，聯康生物科技集團有限公司董事會（「董事會」）成 員載列如下： 周啓明先生 （ 審核委員會主席 ） 任啓民先生 馬青山先生 薪酬委員會 周啓明先生 （ 薪酬委員會主席 ） 梁國龍先生 任啓民先生 馬青山先生 提名委員會 梁國龍先生 （ 提名委員會主席 ） 張清女士 周啓明先生 任啓民先生 馬青山先生 香港，二零二五年三月二十七日 * 僅供識別 以下提供各董事會成員於各董事委員會中所擔任職位的資料： 審核委員會 ...

EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 聯康生物科技集團有限公司 | | 股份代號 | 00690 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 截至2024年12月31日止年度之末期股息及暫停辦理股份過戶登記 | | | 公告日期 | 2025年3月27日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年12月31日 | | 宣派股息 | 每 股 0.00277 HKD | | 股東批准日期 | 2025年5月26日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.00277 HKD | ...

Financial Performance - For the fiscal year ending December 31, 2024, the group's revenue increased by 14.1% year-on-year to approximately HKD 553.0 million[3]. - The net profit for the year surged by 16.8% year-on-year to approximately HKD 82.8 million, marking a historical high[3]. - The gross profit margin improved to 83.4%, up from 81.0% in the previous year[5]. - The group achieved a revenue growth of 14.1% year-on-year, reaching approximately HKD 553.0 million, with net profit soaring by 16.8% to about HKD 82.8 million, marking a historical high[12]. - Gross profit reached approximately HKD 461.1 million, an increase of 17.4% from approximately HKD 392.8 million in 2023, with a gross margin rising by 2.4 percentage points to 83.4%[45]. - The group recorded a patient retention rate exceeding 70% for 博固泰®, indicating strong efficacy and growing recognition among patients and healthcare professionals[15]. - The company reported a significant profit increase of 16.8%, rising from approximately HKD 70.9 million in 2023 to about HKD 82.8 million, driven by the successful launch of new products and strict cost management[62]. Research and Development - Research and development costs as a percentage of revenue increased to 9.5% from 7.3%[5]. - The company completed the drug research and bioequivalence studies for a new product, with formal bioequivalence trials set to commence in 2025[4]. - The group’s R&D expenses increased by 47% year-on-year to approximately HKD 52.3 million, aligning with the progress of its multi-pipeline research[45]. - The company is focusing on research and development in endocrine diseases, ophthalmology, and dermatology, with multiple proprietary biopharmaceuticals and high-value generics in various stages of development[21]. - The company is advancing its R&D pipeline with multiple projects achieving key milestones, including the development of a PTH microneedle patch and a new weight-loss antibody drug[65]. Product Development and Launches - The company successfully launched its self-developed medical aesthetic product, achieving sales of HKD 62.9 million shortly after its market introduction[4]. - The successful commercialization of new products further expanded the group's revenue sources, with the newly launched product 博固泰® generating over HKD 62.9 million in sales within the first ten months[11]. - 博固泰® has rapidly penetrated the market, with 88% of sales coming from orthopedics, osteoporosis, and spinal departments, while rheumatology, endocrinology, and geriatrics contributed 9%[14]. - The company achieved a significant milestone in December 2024 by obtaining approval for the restructured collagen protein dressing and successfully launched its self-developed medical beauty product, Skin Essence®[17]. - The company is enhancing its ophthalmic product portfolio with the sodium diquafosol eye drops, which have been officially accepted for market application in January 2024, addressing the growing demand in the Chinese ophthalmic market with over 360 million dry eye patients[19]. Market Trends and Opportunities - The Chinese pharmaceutical and healthcare industry continued to develop steadily, supported by favorable policies and increased public health awareness[7]. - The Chinese medical beauty market is expected to grow by approximately 10% in 2024, with a projected growth rate of 10-15% over the next four years, indicating a positive development outlook[9]. - The medical beauty market is projected to exceed RMB 600 billion by 2030, positioning the company favorably to capitalize on this expanding opportunity[18]. - The dry eye medication market is expected to surpass RMB 42 billion by 2030, growing at a compound annual growth rate (CAGR) of 28.4%, presenting a significant opportunity for sodium diquafosol[19]. - The pharmaceutical sector in China is expected to grow at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2032, driven by technological innovation and an increasing elderly population[63]. Financial Health and Ratios - The company’s current ratio improved to 2.58 from 2.07, indicating better short-term financial health[5]. - The asset-to-liability ratio increased to 30.50% from 16.19%, reflecting a change in the company's capital structure[5]. - As of December 31, 2024, the group's total assets amounted to approximately HKD 517,552,000, an increase from HKD 409,992,000 as of December 31, 2023[77]. - The group's current assets were approximately HKD 318,779,000, up from HKD 238,096,000 as of December 31, 2023[77]. - The current liabilities stood at HKD 123,496,000, compared to HKD 114,790,000 as of December 31, 2023, resulting in a current liabilities to total assets ratio of 23.9%[77]. Strategic Initiatives - The group plans to apply for FDA approval for 博固泰®, which is a key milestone for entering international markets, with expectations to launch in the U.S. by 2027[16]. - The group aims to expand its sales channels beyond traditional public and private hospitals to include pharmacies, online platforms, and aesthetic medical institutions[64]. - The group is diversifying its sales channels by entering e-commerce, which is anticipated to optimize costs and achieve long-term economies of scale[76]. - The company has established a strategic partnership with active pharmaceutical ingredient (API) suppliers to obtain high-quality raw materials at costs below the industry average, enhancing affordability and competitiveness[20]. - The company announced a collaboration with GBB and TigerMed to develop innovative weight loss drugs, aiming to establish a comprehensive ecosystem from target discovery to commercialization[30]. Shareholder Returns - The board has proposed a final dividend of HKD 0.277 per share, marking the first dividend distribution for the group, reflecting confidence in its performance[13]. - The final dividend is subject to approval at the annual general meeting scheduled for May 26, 2025[81]. - The company plans to propose a final dividend of HKD 0.277 per share for the year ending December 31, 2024, subject to shareholder approval[105]. - The repurchased shares were aimed at reflecting the company's intrinsic value and long-term growth strategy[103].

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 佈 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就本公佈全部或任 何部分內容或因倚賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：0690） 董事會會議的召開日期 茲 通 告 聯 康 生 物 科 技 集 團 有 限 公 司（「 本 公 司 」）將 訂 於 二 零 二 五 年 三 月 二 十 七 日 （ 星期四 ）舉行董事會（「董事會」）會議，目的為（ 其中包括 ）批准本公司截至二零二 四 年 十 二 月三 十 一 日 止 年 度 之 財 務業 績 及 其 發 佈 ， 並 審議 有 關 派 付 末 期 股 息（ 如 有 ）的建議。 承董事會命 聯康生物科技集團有限公司* UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* 主席 梁國龍 香港，二零二五年三月十七日 於 本 公 佈 日 期 ， 董 事 會 包 括 四 名 執 行 董 事 梁 國 龍 先 生（ 主 席 ）、 陳 大 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 佈 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或 任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 電話 ： (852) 2980 1333 傳真 ： (852) 2810 8185 由二零二五年三月十七日起,有關本公司之股份過戶及登記手續將由卓佳證券登記 有限公司辦理。於二零二五年三月十四日下午四時三十分後仍未領取之股票,可於 二零二五年三月十七日起從卓佳證券登記有限公司領取。 承董事會命 UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 更改香港股份過戶登記處 聯康生物科技集團有限公司（「本公司」）董事會宣佈自二零二五年三月十七日起， 本公司之香港股份過戶登記分處將更改為： 卓佳證券登記有限公司 香港 夏慤道16號 遠東金融中心17樓 聯康生物科技集團有限公司* 主席 梁國龍 香港，二零二五年二月十二日 於 本公 佈日 ...